CG Oncology, Inc. Common stock (CGON)vsMerck & Company Inc (MRK)
CGON
CG Oncology, Inc. Common stock
$53.72
-4.23%
HEALTHCARE · Cap: $5.25B
MRK
Merck & Company Inc
$120.79
-2.77%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1296843% more annual revenue ($65.77B vs $5.07M). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
CGON
Avoid34
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CGON.
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1983.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -17.1% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CGON
The strongest argument for CGON centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 1983.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CGON
The primary concerns for CGON are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
CGON profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
CGON carries more volatility with a beta of 0.31 — expect wider price swings.
CGON is growing revenue faster at 1983.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 34/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing pioneering cancer therapies, particularly through its lead product, CG0070, an oncolytic virus therapy designed for non-muscle invasive bladder cancer. Committed to addressing significant unmet medical needs in the oncology space, the company is well-positioned to enhance patient outcomes and transform existing treatment paradigms. As CG Oncology progresses through clinical trials and regulatory processes, its proprietary technology platform sets it apart in the competitive oncology landscape, presenting compelling investment opportunities for institutional investors keen on advancing innovations that may substantially influence cancer care.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?